CD276 anticorps (Biotin)

N° du produit ABIN7077083

Détail du produit anti-CD276 anticorps (Biotin)

Antigène: CD276

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD276 est conjugé à/à la Biotin

Application: Flow Cytometry (FACS)

Attributs du produit: The clone DCN.70, a mouse monoclonal antibody selectively binds with a k type I membrane protein commonly known as CD276, a member of B7-H3 immunoregulatory family. It is not expressed by lymphocytes or granulocytes but weakly expressed on resting monocytes. Increased expression is observed on monocytes derived dendritic cells as well as in a variety of cancer types, including breast, pancreatic, and ovarian cancer. CD276 expression has been correlated with poor survival in ovarian cancer subjects. CD276 blockade, especially when combined with an anti-PD-1 blockade, is a promising strategy for the treatment of B7-H3-expressing NSCLCs that arerefractory to anti-PD-1 therapy, making CD276 a promising clinical molecular target.

Purification: Purified

Pureté: >95 %

Classe de qualité: GMP Grade

Immunogène: Human Dendritic Cells

Clone: DCN-70

Isotype: IgG1 kappa

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS pH 7.2, 0.09 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Détails sur CD276

Antigène: CD276

Autre désignation: CD276 (CD276 Produits)

Synonymes: anticorps sc:d0645, anticorps zgc:158279, anticorps 6030411F23Rik, anticorps AU016588, anticorps B7RP-2, anticorps B7h3, anticorps B7H3, anticorps 4Ig-B7-H3, anticorps B7-H3, anticorps CD276 molecule, anticorps CD276 molecule S homeolog, anticorps CD276 antigen, anticorps Cd276 molecule, anticorps CD276, anticorps cd276.S, anticorps cd276, anticorps Cd276

Sujet: The clone DCN.70, a mouse monoclonal antibody selectively binds with a k type I membrane protein commonly known as CD276, a member of B7-H3 immunoregulatory family. It is not expressed by lymphocytes or granulocytes but weakly expressed on resting monocytes. Increased expression is observed on monocytes derived dendritic cells as well as in a variety of cancer types, including breast, pancreatic, and ovarian cancer. CD276 expression has been correlated with poor survival in ovarian cancer subjects. CD276 blockade, especially when combined with an anti-PD-1 blockade, is a promising strategy for the treatment of B7-H3-expressing NSCLCs that arerefractory to anti-PD-1 therapy, making CD276 a promising clinical molecular target.

ID gène: 80381

UniProt: Q5ZPR3

Pathways: Cancer Immune Checkpoints